Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

The roles of FLT3 in hematopoiesis and leukemia.

Gilliland DG, Griffin JD.

Blood. 2002 Sep 1;100(5):1532-42. Review.

2.

Role of FLT3 in leukemia.

Gilliland DG, Griffin JD.

Curr Opin Hematol. 2002 Jul;9(4):274-81. Review.

PMID:
12042700
3.

FLT3: receptor and ligand.

Drexler HG, Quentmeier H.

Growth Factors. 2004 Jun;22(2):71-3. Review.

PMID:
15253381
4.

The flt3 ligand: a hematopoietic stem cell factor whose activities are distinct from steel factor.

Lyman SD, Brasel K, Rousseau AM, Williams DE.

Stem Cells. 1994;12 Suppl 1:99-107; discussion 108-10. Review.

PMID:
7535149
5.
6.

Overexpression and constitutive activation of FLT3 induces STAT5 activation in primary acute myeloid leukemia blast cells.

Spiekermann K, Bagrintseva K, Schwab R, Schmieja K, Hiddemann W.

Clin Cancer Res. 2003 Jun;9(6):2140-50.

7.

[Mutations of growth factor receptor Flt3 in acute myeloid leukemia: transformation of myeloid cells by Ras-dependent and Ras-independent mechanisms].

Müller-Tidow C, Steur C, Mizuki M, Schwäble J, Brandts C, Berdel WE, Serve H.

Dtsch Med Wochenschr. 2002 Oct 18;127(42):2195-200. German.

PMID:
12397548
8.

Lack of KIT or FMS internal tandem duplications but co-expression with ligands in AML.

Zheng R, Klang K, Gorin NC, Small D.

Leuk Res. 2004 Feb;28(2):121-6. Erratum in: Leuk Res. 2004 Nov;28(14):1241.

PMID:
14654075
9.

Internal tandem duplication of fms-like tyrosine kinase 3 is associated with poor outcome in patients with myelodysplastic syndrome.

Shih LY, Lin TL, Wang PN, Wu JH, Dunn P, Kuo MC, Huang CF.

Cancer. 2004 Sep 1;101(5):989-98.

10.
11.

Normal and oncogenic FLT3.

Naoe T, Kiyoi H.

Cell Mol Life Sci. 2004 Dec;61(23):2932-8. Review.

PMID:
15583855
12.

Effects of MLN518, a dual FLT3 and KIT inhibitor, on normal and malignant hematopoiesis.

Griswold IJ, Shen LJ, La Rosée P, Demehri S, Heinrich MC, Braziel RM, McGreevey L, Haley AD, Giese N, Druker BJ, Deininger MW.

Blood. 2004 Nov 1;104(9):2912-8. Epub 2004 Jul 8.

13.

Mutant FLT3 signaling contributes to a block in myeloid differentiation.

Zheng R, Small D.

Leuk Lymphoma. 2005 Dec;46(12):1679-87. Review.

PMID:
16263569
14.

Flt3 receptor tyrosine kinase as a drug target in leukemia.

Schmidt-Arras D, Schwäble J, Böhmer FD, Serve H.

Curr Pharm Des. 2004;10(16):1867-83. Review.

PMID:
15180525
16.

Roles of tyrosine 589 and 591 in STAT5 activation and transformation mediated by FLT3-ITD.

Rocnik JL, Okabe R, Yu JC, Lee BH, Giese N, Schenkein DP, Gilliland DG.

Blood. 2006 Aug 15;108(4):1339-45. Epub 2006 Apr 20.

17.

FLT3/ITD mutation signaling includes suppression of SHP-1.

Chen P, Levis M, Brown P, Kim KT, Allebach J, Small D.

J Biol Chem. 2005 Feb 18;280(7):5361-9. Epub 2004 Dec 1.

18.

FMS-like tyrosine kinase 3 in normal hematopoiesis and acute myeloid leukemia.

Parcells BW, Ikeda AK, Simms-Waldrip T, Moore TB, Sakamoto KM.

Stem Cells. 2006 May;24(5):1174-84. Epub 2006 Jan 12. Review.

19.
20.

Risk assessment in patients with acute myeloid leukemia and a normal karyotype.

Bienz M, Ludwig M, Leibundgut EO, Mueller BU, Ratschiller D, Solenthaler M, Fey MF, Pabst T.

Clin Cancer Res. 2005 Feb 15;11(4):1416-24. Erratum in: Clin Cancer Res. 2005 Aug 1;11(15):5659.

Supplemental Content

Support Center